enVVeno Medical (NASDAQ:NVNO), Inc. is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.
The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion. By housing the catheter entry point beneath the skin, the system is engineered to reduce catheter‐related bloodstream infections (CRBSIs) and to improve patient mobility and quality of life during extended treatment regimens. enVVeno Medical is currently conducting clinical studies to gather safety and performance data in collaboration with U.S. healthcare institutions.
Founded in 2018 and headquartered in Durham, North Carolina, enVVeno Medical serves hospitals, infusion centers, and home healthcare providers across the United States. The company is led by President and Chief Executive Officer Frank Douette, whose leadership team brings extensive experience in medical device development, regulatory affairs and commercialization strategies. The board and management draw on backgrounds in cardiovascular and vascular access markets to guide product development and regulatory pathways.
As a NASDAQ‐listed entity, enVVeno Medical is positioned to advance its Freedom platform through pivotal clinical trials and toward regulatory approval. By targeting an estimated multi‐billion dollar vascular access market, the company seeks to offer clinicians and patients a safer, more convenient option for long‐term intravenous therapy and to establish a new standard in vascular access care.
